Strand TherapeuticsCambridge, MALife SciencesCohort: 2018-2019
Strand Therapeutics has developed a drug candidate made of self-replicating mRNA that can make cancers more responsive to immunotherapy. Their synthetic mRNA programming technology makes their drug candidate safer than other gene therapies, more effective in patients and cheaper to manufacture.
The startup represented here is a graduate of Endless Frontier Labs’ predecessor program, called Creative Destruction Lab-New York City, operated by NYU in partnership with University of Toronto during 2018-2019. The Endless Frontier Labs has no current engagement or affiliation with the Creative Destruction Lab.